Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality

A. M. J. Reedijk, K. Klein, J. W. W. Coebergh, L. C. Kremer, A. G. Dinmohamed, V. de Haas, A. B. Versluijs, G. J. Ossenkoppele, H. B. Beverloo, R. Pieters, C. M. Zwaan, G. J. L. Kaspers, H. E. Karim-Kos

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Variation in survival of pediatric acute myeloid leukemia (pAML) over time and between Western European countries exists. The aim of the current study is to assess the progress made for the Dutch pAML population (0–17 years) during 1990–2015, based on trends in incidence, survival and mortality. Data from the population-based Netherlands Cancer Registry were merged with leukemia-related characteristics and treatment specifics from the Dutch Childhood Leukemia Study Group (Dutch Childhood Oncology Group (DCOG) from 2002 onwards). Mortality data (1980–2016) were obtained from the cause of death registry of Statistics Netherlands. Trend analyses were performed over time and by treatment protocol. Between 1990 and 2015, a total of 635 children aged 0–17 years were diagnosed with AML for an average of 25 patients (range 18–36) per year. There was a slight increase in the incidence at age 1–4 years (average annual percentage change (AAPC) of +2.2% per year (95% CI 0.8–3.5, p < 0.01)). Overall, the 5-year survival significantly improved over the past 26 years and nearly doubled from 40% in the early 1990s to 74% in 2010–2015. Multivariable analysis showed a 49% reduction in risk of death for pAML patients treated according to the latest DB-AML 01 protocol (p = 0.03). The continuing decrease of mortality (AAPC −2.8% per year (95% CI −4.1 to −1.5)) supports the conclusion of true progress against pAML in the Netherlands.
Original languageEnglish
JournalLeukemia
DOIs
Publication statusE-pub ahead of print - 2018

Cite this

Reedijk, A. M. J. ; Klein, K. ; Coebergh, J. W. W. ; Kremer, L. C. ; Dinmohamed, A. G. ; de Haas, V. ; Versluijs, A. B. ; Ossenkoppele, G. J. ; Beverloo, H. B. ; Pieters, R. ; Zwaan, C. M. ; Kaspers, G. J. L. ; Karim-Kos, H. E. / Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. In: Leukemia. 2018.
@article{c086571382a9477aba30ac08c4b73517,
title = "Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality",
abstract = "Variation in survival of pediatric acute myeloid leukemia (pAML) over time and between Western European countries exists. The aim of the current study is to assess the progress made for the Dutch pAML population (0–17 years) during 1990–2015, based on trends in incidence, survival and mortality. Data from the population-based Netherlands Cancer Registry were merged with leukemia-related characteristics and treatment specifics from the Dutch Childhood Leukemia Study Group (Dutch Childhood Oncology Group (DCOG) from 2002 onwards). Mortality data (1980–2016) were obtained from the cause of death registry of Statistics Netherlands. Trend analyses were performed over time and by treatment protocol. Between 1990 and 2015, a total of 635 children aged 0–17 years were diagnosed with AML for an average of 25 patients (range 18–36) per year. There was a slight increase in the incidence at age 1–4 years (average annual percentage change (AAPC) of +2.2{\%} per year (95{\%} CI 0.8–3.5, p < 0.01)). Overall, the 5-year survival significantly improved over the past 26 years and nearly doubled from 40{\%} in the early 1990s to 74{\%} in 2010–2015. Multivariable analysis showed a 49{\%} reduction in risk of death for pAML patients treated according to the latest DB-AML 01 protocol (p = 0.03). The continuing decrease of mortality (AAPC −2.8{\%} per year (95{\%} CI −4.1 to −1.5)) supports the conclusion of true progress against pAML in the Netherlands.",
author = "Reedijk, {A. M. J.} and K. Klein and Coebergh, {J. W. W.} and Kremer, {L. C.} and Dinmohamed, {A. G.} and {de Haas}, V. and Versluijs, {A. B.} and Ossenkoppele, {G. J.} and Beverloo, {H. B.} and R. Pieters and Zwaan, {C. M.} and Kaspers, {G. J. L.} and Karim-Kos, {H. E.}",
year = "2018",
doi = "10.1038/s41375-018-0314-7",
language = "English",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. / Reedijk, A. M. J.; Klein, K.; Coebergh, J. W. W.; Kremer, L. C.; Dinmohamed, A. G.; de Haas, V.; Versluijs, A. B.; Ossenkoppele, G. J.; Beverloo, H. B.; Pieters, R.; Zwaan, C. M.; Kaspers, G. J. L.; Karim-Kos, H. E.

In: Leukemia, 2018.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality

AU - Reedijk, A. M. J.

AU - Klein, K.

AU - Coebergh, J. W. W.

AU - Kremer, L. C.

AU - Dinmohamed, A. G.

AU - de Haas, V.

AU - Versluijs, A. B.

AU - Ossenkoppele, G. J.

AU - Beverloo, H. B.

AU - Pieters, R.

AU - Zwaan, C. M.

AU - Kaspers, G. J. L.

AU - Karim-Kos, H. E.

PY - 2018

Y1 - 2018

N2 - Variation in survival of pediatric acute myeloid leukemia (pAML) over time and between Western European countries exists. The aim of the current study is to assess the progress made for the Dutch pAML population (0–17 years) during 1990–2015, based on trends in incidence, survival and mortality. Data from the population-based Netherlands Cancer Registry were merged with leukemia-related characteristics and treatment specifics from the Dutch Childhood Leukemia Study Group (Dutch Childhood Oncology Group (DCOG) from 2002 onwards). Mortality data (1980–2016) were obtained from the cause of death registry of Statistics Netherlands. Trend analyses were performed over time and by treatment protocol. Between 1990 and 2015, a total of 635 children aged 0–17 years were diagnosed with AML for an average of 25 patients (range 18–36) per year. There was a slight increase in the incidence at age 1–4 years (average annual percentage change (AAPC) of +2.2% per year (95% CI 0.8–3.5, p < 0.01)). Overall, the 5-year survival significantly improved over the past 26 years and nearly doubled from 40% in the early 1990s to 74% in 2010–2015. Multivariable analysis showed a 49% reduction in risk of death for pAML patients treated according to the latest DB-AML 01 protocol (p = 0.03). The continuing decrease of mortality (AAPC −2.8% per year (95% CI −4.1 to −1.5)) supports the conclusion of true progress against pAML in the Netherlands.

AB - Variation in survival of pediatric acute myeloid leukemia (pAML) over time and between Western European countries exists. The aim of the current study is to assess the progress made for the Dutch pAML population (0–17 years) during 1990–2015, based on trends in incidence, survival and mortality. Data from the population-based Netherlands Cancer Registry were merged with leukemia-related characteristics and treatment specifics from the Dutch Childhood Leukemia Study Group (Dutch Childhood Oncology Group (DCOG) from 2002 onwards). Mortality data (1980–2016) were obtained from the cause of death registry of Statistics Netherlands. Trend analyses were performed over time and by treatment protocol. Between 1990 and 2015, a total of 635 children aged 0–17 years were diagnosed with AML for an average of 25 patients (range 18–36) per year. There was a slight increase in the incidence at age 1–4 years (average annual percentage change (AAPC) of +2.2% per year (95% CI 0.8–3.5, p < 0.01)). Overall, the 5-year survival significantly improved over the past 26 years and nearly doubled from 40% in the early 1990s to 74% in 2010–2015. Multivariable analysis showed a 49% reduction in risk of death for pAML patients treated according to the latest DB-AML 01 protocol (p = 0.03). The continuing decrease of mortality (AAPC −2.8% per year (95% CI −4.1 to −1.5)) supports the conclusion of true progress against pAML in the Netherlands.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85058855833&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30568171

U2 - 10.1038/s41375-018-0314-7

DO - 10.1038/s41375-018-0314-7

M3 - Article

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -